Tech Company Financing Transactions
invIOs Funding Round
invIOs, based in Vienna, secured $8.9 million from Ligand Pharmaceuticals and private investors.
Transaction Overview
Company Name
Announced On
10/15/2024
Transaction Type
Venture Equity
Amount
$8,900,000
Round
Series A
Investors
Proceeds Purpose
This funding secures ongoing pipeline progress and achievement of clinical and preclinical milestones through 2025.
Company Information
Company Status
Private & Independent
Industry
FinTech
Mailing Address
Campus-Vienna-Biocenter 5
Vienna, 1030
Austria
Vienna, 1030
Austria
Phone
Website
Email Address
Overview
invIOs is a PRIVATE BIOTECH COMPANY focusing on discovering and developing next-generation cancer therapeutics. We are pioneers in R&D of drug candidates targeting novel immune checkpoints, and in IMMUNE SYSTEM ACTIVATION. We LAUNCHED IN 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Manfred Reichl
Chief Executive Officer
Peter Llewellyn-Davies
Chief Scientific Officer
Romana Gugenberger
Browse more venture capital transactions:
Prev: 10/15/2024: REsurety venture capital transaction
Next: 10/15/2024: Decagon venture capital transaction
Share this article
News on VC Transactions
We record funding rounds that are announced publicly. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs